Global distribution of lung cancer staging at diagnosis: a systematic review

Lung cancer remains the leading cause of cancer-related mortality worldwide, with stage at diagnosis significantly influencing survival outcomes. This systematic review evaluates global variations in lung cancer stage distribution at diagnosis and examines the associations of socioeconomic factors and screening programs with these disparities. We conducted a systematic review following PRISMA guidelines, searching PubMed, Embase, and grey literature up to August 14, 2024, to identify population- or hospital-based cancer registry data on lung cancer staging. Data from 36 countries were analyzed, focusing on the proportion of distant metastatic cases. We assessed associations with Human Development Index (HDI) and Socio-Demographic Index (SDI) using case-number-weighted linear regression model and evaluated time trends in countries with and without screening programs. Subgroup analyses explored variations by sex, age, and tumor type. Among the 35 countries analyzed in the main study, the median proportion of lung cancer cases diagnosed with distant metastasis was 50.8% (interquartile range: 44.8%–59.2%), ranging from 30.4% in Hungary to 81.3% in Brunei Darussalam. No significant associations were observed between HDI ( β = 2.274, P = 0.876) or SDI ( β = − 7.332, P = 0.420) and the proportion of lung cancer cases with distant metastases. In countries implementing screening programs, the proportion of metastatic cases has declined, e.g., in the United States (56.5% in 2004 to 48.5% in 2021) and England (54.7% in 2013 to 48.7% in 2021), with increased early-stage incidence in the United States and Republic of Korea. The proportion of patients in the metastatic stage is higher among males, younger patients, and those with small cell lung cancer. Significant global disparities in lung cancer stage at diagnosis highlight the critical role of screening programs in reducing metastatic cases. Enhancing early detection in resource-limited settings and standardizing registries are vital to improve outcomes and equity.

Authors

Institutions

Publication Details

Journal
BMC Public Health
Published
2026-09-05
DOI
https://doi.org/10.1186/s12889-026-29310-z
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Global distribution of lung cancer staging at diagnosis: a systematic review

Yuelun Zhang, L. Guo, Haiyan Yang, Xinran Cheng et al.
BMC Public Health
Lung Cancer Treatments and Mutations
article

Global distribution of lung cancer staging at diagnosis: a systematic review

Yuelun Zhang, L. Guo, Haiyan Yang, Xinran Cheng, Yan Zheng, Lin Cai, Jiani Yuan, Chenxin Zhu, Le Wang, Min Dai, Yanyan Liu, Zeyang Li, Hongda Chen
article en

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide, with stage at diagnosis significantly influencing survival outcomes. This systematic review evaluates global variations in lung cancer stage distribution at diagnosis and examines the associations of socioeconomic factors and screening programs with these disparities. We conducted a systematic review following PRISMA guidelines, searching PubMed, Embase, and grey literature up to August 14, 2024, to identify population- or hospital-based cancer registry data on lung cancer staging. Data from 36 countries were analyzed, focusing on the proportion of distant metastatic cases. We assessed associations with Human Development Index (HDI) and Socio-Demographic Index (SDI) using case-number-weighted linear regression model and evaluated time trends in countries with and without screening programs. Subgroup analyses explored variations by sex, age, and tumor type. Among the 35 countries analyzed in the main study, the median proportion of lung cancer cases diagnosed with distant metastasis was 50.8% (interquartile range: 44.8%–59.2%), ranging from 30.4% in Hungary to 81.3% in Brunei Darussalam. No significant associations were observed between HDI ( β = 2.274, P = 0.876) or SDI ( β = − 7.332, P = 0.420) and the proportion of lung cancer cases with distant metastases. In countries implementing screening programs, the proportion of metastatic cases has declined, e.g., in the United States (56.5% in 2004 to 48.5% in 2021) and England (54.7% in 2013 to 48.7% in 2021), with increased early-stage incidence in the United States and Republic of Korea. The proportion of patients in the metastatic stage is higher among males, younger patients, and those with small cell lung cancer. Significant global disparities in lung cancer stage at diagnosis highlight the critical role of screening programs in reducing metastatic cases. Enhancing early detection in resource-limited settings and standardizing registries are vital to improve outcomes and equity.

BMC Public Health
Chinese Academy of Sciences (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking Union Medical College Hospital (CN), Zhengzhou University (CN), Zhejiang Cancer Hospital (CN), Henan Cancer Hospital (CN), Imperial College London (GB)
China Postdoctoral Science Foundation
Openalex Percentile: Top 11%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.